162 related articles for article (PubMed ID: 35558920)
21. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
[TBL] [Abstract][Full Text] [Related]
22. Novel spirocyclic tranylcypromine derivatives as lysine-specific demethylase 1 (LSD1) inhibitors.
Shi Y; Wu YR; Su MB; Shen DH; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
RSC Adv; 2018 Jan; 8(3):1666-1676. PubMed ID: 35540911
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
[TBL] [Abstract][Full Text] [Related]
24. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).
Li Z; Ding L; Li Z; Wang Z; Suo F; Shen D; Zhao T; Sun X; Wang J; Liu Y; Ma L; Zhao B; Geng P; Yu B; Zheng Y; Liu H
Acta Pharm Sin B; 2019 Jul; 9(4):794-808. PubMed ID: 31384539
[TBL] [Abstract][Full Text] [Related]
25. A selective phenelzine analogue inhibitor of histone demethylase LSD1.
Prusevich P; Kalin JH; Ming SA; Basso M; Givens J; Li X; Hu J; Taylor MS; Cieniewicz AM; Hsiao PY; Huang R; Roberson H; Adejola N; Avery LB; Casero RA; Taverna SD; Qian J; Tackett AJ; Ratan RR; McDonald OG; Feinberg AP; Cole PA
ACS Chem Biol; 2014 Jun; 9(6):1284-93. PubMed ID: 24707965
[TBL] [Abstract][Full Text] [Related]
26. Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts.
Valente S; Rodriguez V; Mercurio C; Vianello P; Saponara B; Cirilli R; Ciossani G; Labella D; Marrocco B; Monaldi D; Ruoppolo G; Tilset M; Botrugno OA; Dessanti P; Minucci S; Mattevi A; Varasi M; Mai A
Eur J Med Chem; 2015 Apr; 94():163-74. PubMed ID: 25768700
[TBL] [Abstract][Full Text] [Related]
27. Discovery of vanadium complexes bearing tridentate schiff base ligands as novel LSD1 inhibitors.
Lu LP; Liu JH; Cen SH; Jiang YL; Hu GQ
Bioorg Med Chem Lett; 2019 Feb; 29(4):681-683. PubMed ID: 30611616
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and evaluation of novel cyclic Peptide inhibitors of lysine-specific demethylase 1.
Kumarasinghe IR; Woster PM
ACS Med Chem Lett; 2014 Jan; 5(1):29-33. PubMed ID: 24883177
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
30. Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors.
Niwa H; Sato S; Handa N; Sengoku T; Umehara T; Yokoyama S
ChemMedChem; 2020 May; 15(9):787-793. PubMed ID: 32166890
[TBL] [Abstract][Full Text] [Related]
31. Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing.
Li Z; Qin T; Li Z; Zhao X; Zhang X; Zhao T; Yang N; Miao J; Ma J; Zhang Z
Eur J Med Chem; 2021 Dec; 225():113778. PubMed ID: 34416665
[TBL] [Abstract][Full Text] [Related]
32. A novel mammalian flavin-dependent histone demethylase.
Karytinos A; Forneris F; Profumo A; Ciossani G; Battaglioli E; Binda C; Mattevi A
J Biol Chem; 2009 Jun; 284(26):17775-82. PubMed ID: 19407342
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
34. Novel polyamine analogues: from substrates towards potential inhibitors of monoamine oxidases.
Bonaiuto E; Milelli A; Cozza G; Tumiatti V; Marchetti C; Agostinelli E; Fimognari C; Hrelia P; Minarini A; Di Paolo ML
Eur J Med Chem; 2013; 70():88-101. PubMed ID: 24140951
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors.
Wang S; Li ZR; Suo FZ; Yuan XH; Yu B; Liu HM
Eur J Med Chem; 2019 Apr; 167():388-401. PubMed ID: 30780087
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
37. Expression profile of H3K4 demethylases with their clinical and pathological correlation in patients with clear cell renal cell carcinoma.
Kumar A; Kumari N; Nallabelli N; Sharma U; Rai A; Singh SK; Kakkar N; Prasad R
Gene; 2020 May; 739():144498. PubMed ID: 32097694
[TBL] [Abstract][Full Text] [Related]
38. Sanguinarine, identified as a natural alkaloid LSD1 inhibitor, suppresses lung cancer cell growth and migration.
Qin TT; Li ZH; Li LX; Du K; Yang JG; Zhang ZQ; Wu XX; Ma JL
Iran J Basic Med Sci; 2022 Jun; 25(6):781-788. PubMed ID: 35949313
[TBL] [Abstract][Full Text] [Related]
39. Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation.
Li ZR; Suo FZ; Guo YJ; Cheng HF; Niu SH; Shen DD; Zhao LJ; Liu ZZ; Maa M; Yu B; Zheng YC; Liu HM
Bioorg Chem; 2020 Apr; 97():103648. PubMed ID: 32065882
[TBL] [Abstract][Full Text] [Related]
40. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
